Pfizer is expanding its multibillion-dollar cost-cutting effort that began in 2023, announcing $1.7 billion in new planned ...

AstraZeneca said it was shutting down a Phase 3 Truqap study in a hard-to-treat form of prostate cancer after an interim ...

Octagon Therapeutics, led by CEO Isaac Stoner, is shutting down after halting work on B cell immunomodulator and facing ...

Vaxart said a stop-work order has been lifted on its next-generation Covid-19 vaccine efforts planned under a Biden-era ...

As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...

Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...

Daiichi Sankyo reaffirms US manufacturing expansion, including for Enhertu, will help with Trump's proposed tariffs. $350M ...

Boehringer Ingelheim's zongertinib shows promising results in lung cancer trial with 71% response rate and 14-month median ...

Vertex Pharmaceuticals, Amgen and Jazz Pharmaceuticals are among companies that received a positive opinion from European ...

Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations.

Globally, approximately 300 million people are grappling with obesity, a complex disease that has a profound impact on a ...

France’s national public health agency is suspending immunization of adults 65 years and older with Valneva’s chikungunya ...